First Patient Dosed in Clinical Trial of IB-T101 for ccRCC
“This is a major milestone for Inceptor Bio as we advance IB-T101 into the clinic,” said Dr. Matthias Schroff, Chief Executive Officer of Inceptor Bio. “Similar to elite athletes training at high elevation, T cells conditioned in challenging environments develop the attributes needed to outperform in solid tumors. With the support and confidence of our investors, we are focused on advancing our lead program with the goal of delivering a best-in-class therapy that has the potential to change the treatment paradigm for patients facing these challenging cancers.”
Share:
More News
“We would like to thank Novartis for this groundbreaking research collaboration which enabled us to launch our activities in the field of targeted radiopharmaceuticals. We developed know-how, attracted a strong team of experts and evolved our Radio-DARPin platform. As it stands today, we are not planning to integrate these programs
“Adding dordaviprone to our oncology R&D pipeline will further diversify our portfolio with a medicine that addresses a significant unmet need with no other FDA-approved therapies and limited treatment options for this patient population. If approved, dordaviprone has the potential to rapidly become a standard of care for a rare
“We are thrilled to share that the first trial site has been initiated and activation of additional clinical sites continues,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. “Considering the strength and durability of the clinical responses in our VERSATILE-002 study, we are pleased to get
“The HARMONi-2 study demonstrated that in the intent-to-treat population, ivonescimab monotherapy significantly extended progression-free survival (PFS) compared to pembrolizumab monotherapy, reducing the risk of disease progression by 49% (PFS HR 0.51, P<0.0001). Subgroup analyses revealed that regardless of patients’ age, gender, ECOG performance status, PD-L1 expression, histological type, or the
